Fresh leadership has been announced for the CEO Advisory Committee of the International Generic and Biosimilar medicines Association, with Insud Pharma chief executive Lucas Sigman moving up from his previous position of vice-chair to become chair. Allan Oberman, president and CEO of Apotex, has been named as the new vice-chair.
Insud And Apotex Chiefs Take Lead As IGBA Shuffles CEO Committee
Global Off-Patent Body Names Chair And Vice-Chair
Insud Pharma chief executive Lucas Sigman has moved up to lead the IGBA’s CEO Advisory Committee, replacing Lupin chief Vinita Gupta at the helm. Meanwhile, Apotex president and CEO Allan Oberman has become vice-chair.
More from Leadership
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
• By
With Celltrion having just received approval for its US Actemra (tocilizumab) biosimilar and having just launched its ustekinumab rival to Stelara – and with the introduction of the Korean developer’s denosumab rivals to Prolia and Xgeva just around the corner – 2025 is set to be a busy year, Celltrion USA chief commercial officer Thomas Nusbickel tells Generics Bulletin.
Fresenius Kabi is drawing closer to the conclusion of its Vision 2026 strategic roadmap. The company’s CEO, Pierluigi Antonelli, talks to Generics Bulletin about the company’s results so far and how it’s investments in biosimilars, acquisitions and manufacturing is paying off.
• By
IGBA secretary general Susana Almeida takes Generics Bulletin through an almost two-decade journey of developing global regulatory convergence and the next goals for the off-patent industry.
More from Generics Bulletin
• By
Off-patent drug trade groups expressed their concerns that personnel and expertise cuts will affect the agency’s ability to review and approve generics and biosimilars.
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
FDA staffing cuts are making negotiation preparations more difficult, but also could mean the result is a smaller user fee renewal package.